Drugs.com - Clinical Trials

Icotrokinra Results Show Significant Skin Clearance in Patients with Difficult-to-Treat Scalp and Genital Psoriasis

SPRING HOUSE, Pa. (May 9, 2025) – Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-TOTALa study investigating icotrokinra (JNJ-2113), the first-in-class investigational targeted oral peptide that selectively...

May 12, 2025 - 04:25
 0
Icotrokinra Results Show Significant Skin Clearance in Patients with Difficult-to-Treat Scalp and Genital Psoriasis
SPRING HOUSE, Pa. (May 9, 2025) – Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-TOTALa study investigating icotrokinra (JNJ-2113), the first-in-class investigational targeted oral peptide that selectively...
Read More

Tags:

Previous Article

Zepbound (tirzepatide) Showed Superior Weight Loss Over Wegovy (semaglutide) in ...

Next Article

Boehringer Ingelheim Starts Phase II Study of BI 1584862, Potential First-in-Cla...

Related Posts

Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025

Genentech and Roche Present Novel Therapeutic and Diagn...

May 12, 2025  0

Sebela Pharmaceuticals Announces Positive Topline Results from Phase 3 TRIUMpH Program of Tegoprazan in GERD

Sebela Pharmaceuticals Announces Positive Topline Resul...

May 7, 2025  0

FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

FDA Announces Plan to Phase Out Animal Testing Requirem...

May 12, 2025  0